WO2009064082A1 - Composition à extrait de galla rhois pour la prévention et le traitement de l'obésité via le mécanisme d'autophagie - Google Patents

Composition à extrait de galla rhois pour la prévention et le traitement de l'obésité via le mécanisme d'autophagie Download PDF

Info

Publication number
WO2009064082A1
WO2009064082A1 PCT/KR2008/006294 KR2008006294W WO2009064082A1 WO 2009064082 A1 WO2009064082 A1 WO 2009064082A1 KR 2008006294 W KR2008006294 W KR 2008006294W WO 2009064082 A1 WO2009064082 A1 WO 2009064082A1
Authority
WO
WIPO (PCT)
Prior art keywords
galla rhois
obesity
extract
fraction
prevention
Prior art date
Application number
PCT/KR2008/006294
Other languages
English (en)
Inventor
Se Chan Kang
Han Choi
Young Jun Cheong
Young Hwan Jung
Hee Jeong Kim
Eun Hwa Son
Original Assignee
Igsbio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020080104394A external-priority patent/KR101078002B1/ko
Application filed by Igsbio filed Critical Igsbio
Publication of WO2009064082A1 publication Critical patent/WO2009064082A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Definitions

  • the present invention relates to a composition comprising a Galla Rhois extract for the prevention and treatment of obesity based on the mechanism of autophage inducing system.
  • Obesity is a body condition referring to a state when an excess body fat relative to body weight has accumulated in the body due to the imbalance between energy supply and consumption by inappropriate control by the adipocytes, which are present about 20 billion or more in the body. If the number of adipocytes is increased and energy and triglycerides are excessively accumulated therein, the size of adipocytes is increased, leading to obesity.
  • Primary function of adipocytes is to store and release energy in the body. When energy supply exceeds energy consumption, most of the excess energy is converted into triglycerides and accumulated in the adipocytes.
  • the accumulated triglycerides are degraded into free fatty acids and glycerol to be used as an energy source.
  • the accumulation of triglycerides in the adipocytes due to the energy surplus is a major cause of obesity.
  • Korean Patent No. 588469 discloses a method of inhibiting the differentiation of adipocytes and accumulation of fats in the differentiated adipocytes by using shogaol isolated from ginger. The patent merely discloses that shogaol inhibits the accumulation of fats in adipocytes, but there was no teaching regarding the effect of preventing obesity or reducing body weight in an obesity- induced animal model, thus limiting its applicability.
  • autophagocytosis Different from natural death or necrosis which involves in the death of a whole cell, autophagocytosis, a new type of cell death, relates to the death and regeneration of intracellular organelles such as mitochondria, endoplasmic reticulum and the like. It was believed that these intracellular organelles are usually maintained under static conditions, but recent study has discovered that they undergo a continuous process of apoptosis and regeneration. The old intracellular organelle undergone a degenerative change becomes extinct through such a process and is provided as a nutrient source for the regeneration of a new intracellular organelle. Autophage inducing system (autophagocytosis) can prevent the death of a whole cell or induce the same via the apoptosis and regeneration process of intracellular organelles.
  • autophage inducing system autophagocytosis
  • Galla Rhois is a nest of a parasitic bug, Mellaphis chinensis Bell, formed in the leaves of Rhus javanica L. or other Anacardiaceae, and is primarily composed of gallotannin (50-70%) such as gallic acid, pentagalloyl glucose and the like.
  • gallotannin 50-70% such as gallic acid, pentagalloyl glucose and the like.
  • the present invention has found that an extract of Galla Rhois can inhibit the differentiation of adipocytes based on the mechanism of autophagocytosis and prevent triglycerides from accumulating in the differentiated adipocytes.
  • the present invention has confirmed in an obesity-induced animal model that the Galla Rhois extract exhibits such inhibitory activities of reducing the accumulation of abdominal fats, suppressing the accumulation of liver and epididymal fats, and inhibiting body weight gain. It has been proved that thus confirmed inhibitory activities of the Galla Rhois extract is identical to or higher than those of the prior art obesity inhibitor well-known in the art. Until now it has been reported that the Galla Rhois extract is effective for the prevention and treatment of diabetes through a protective action on beta-cell damage, but there is no report that it can be used as an anti-obesity drug by inhibiting the differentiation of adipocytes and accumulation of fats in the differentiated adipocytes via autophagocytosis.
  • the present inventors have therefore endeavored to develop a new herbal medicine component having higher anti-obesity inhibitory activities than the prior art anti-obesity drugs without causing any side effects, and found that the extract and fraction of Galla Rhois inhibit the differentiation of adipocytes based on the mechanism of autophagocytosis, prevent triglycerides from accumulating in the differentiated adipocytes, and therefore, exhibit remarkable anti-obesity activities in an obesity-induced animal model without showing cytotoxicity.
  • the present invention is directed to overcoming the above deficiencies in the art.
  • One of the objectives of the present invention is to provide a composition for the prevention and treatment of obesity comprising an extract of Galla Rhois or fractions thereof as an active ingredient.
  • Another objective of the present invention is to provide health foods comprising an extract of Galla Rhois or fractions thereof as an active ingredient.
  • composition for the prevention and treatment of obesity comprising an extract of Galla Rhois or fractions thereof as an active ingredient.
  • a method of isolating the active ingredient from Galla Rhois is provided.
  • health foods comprising an extract of Galla Rhois or fractions thereof as an active ingredient.
  • the present invention relates to a composition for the prevention and treatment of obesity comprising an extract of Galla Rhois or fractions thereof as an active ingredient wherein the Galla Rhois is a nest of parasitic bug, Mellaphis chinensis Bell, formed in the leaves of Rhus javanica L. or other Anacardiaceae. Since the composition of the present invention can prevent the differentiation of preadipocytes into adipocytes via autophagocytosis and inhibit the accumulation of fats in the differentiated adipocytes, it can be effectively used for the prevention and treatment of obesity in the form of a food or a pharmaceutical composition without causing side effects.
  • Fig. 1 is a schematic diagram illustrating a method of isolating an ethylacetate fraction from an extract of Galla Rhois according to the present invention.
  • Fig. 2 is a schematic diagram illustrating a method of preparing an extract of Galla Rhois comprising active ingredients according to the present invention.
  • Fig. 3 is a graph showing autophagocytotic activities of the Galla Rhois fraction comprising active ingredients according to the present invention at Day 4 during the induction of adipocyte differentiation.
  • Fig. 4 is a graph showing autophagocytotic activities of the Galla Rhois fraction comprising active ingredients according to the present invention at Day 4 after the adipocyte differentiation.
  • Fig. 5 is a photograph showing autophagocytotic activities of the Galla Rhois extract comprising active ingredients according to the present invention at Day 4 after the adipocyte differentiation.
  • Fig. 6 is a graph showing inhibitory activities of the Galla Rhois extract comprising active ingredients according to the present invention on body weight gain in an obesity-induced animal model.
  • the present invention has found that a Galla Rhois extract and organic solvent fractions thereof inhibit the differentiation of preadipocytes into adipocytes via autophagocytosis, prevent the accumulation of fats in differentiated adipocytes, suppress the accumulation of body fats and body weight gain, and reduce blood triglyceride and low density lipoprotein levels in an obesity-induced animal model. Therefore, the present invention relates to the Galla Rhois extract which can be used as a composition for the prevention and treatment of obesity.
  • Galla Rhois is extracted with alcohol, to thereby obtain an alcohol extract.
  • the alcohol suitable for the present invention may be preferably selected from the group consisting of methanol, ethanol, isopropyl alcohol, propyl alcohol, butyl alcohol and mixtures thereof.
  • the alcohol extract is suspended in water, subjected to fractionation with normal hexane, dichloromethane and ethylacetate in order, and then, concentrated under reduced pressure, to thereby obtain an ethylacetate fraction.
  • the ethylacetate fraction is then subjected to silica gel chromatography so as to obtain active fractions.
  • the silica gel chromatography is carried out according to a gradient elution system by using a mixed solvent of ethylacetate and methanol (98:5 ⁇ 80:20), to thereby obtain the active fractions (Rf: 4.5, in a mixed solvent (3:7) of hexane and ethylacetate).
  • purified active ingredient is a compound represented by the following Formula 1.
  • n is an integer of from 1 to 2. It has been confirmed that thus obtained Galla Rhois alcohol extract and fraction thereof inhibit the differentiation of preadipocytes (3T3-L1) into adipocytes via autophagocytosis, prevent the accumulation of fat in the differentiated adipocytes, and suppress body weight gain in an obesity-induced animal model. Therefore, the composition comprising the Galla Rhois extract and fraction thereof can be effectively used in the prevention and treatment of obesity by inhibiting the differentiation of adipocytes via autophagocytosis and suppressing the accumulation of fats in differentiated adipocytes.
  • composition comprising the Galla Rhois extract or fraction thereof as an active ingredient can be clinically administered as various oral formulations, for example, tablets, troches, lozenge, soluble or oily suspensions, powders or granules, emulsions, hard or soft capsules, syrups or elixirs.
  • the tablet and capsule formulations can be prepared by using binders such as lactose, sucrose, sorbitol, mannitol, starch, amylopectin, cellulose or gelatin; excipients such as dicalcium phosphate; disintegrating agents such as corn starch or sweet potato starch; and lubricating agents such as magnesium strearate, calcium stearate, sodium stearylfumaric acid or polyethylene glycol.
  • the capsule formulations can be prepared by using liquid carriers such as fatty oil in addition to the additives described above.
  • composition comprising the Galla Rhois extract or fraction thereof as an active ingredient can be clinically administered via various parental routes including subcutaneous injection, intravenous injection, intramuscular injection, intrathoracic injection and the like.
  • the parental formulations can be prepared by mixing the composition with stabilizers or buffering agents and filling the resulting solution in an ampule or a vial as a unit dosage form.
  • the typical daily dose of the Galla Rhois extract or fraction thereof comprising active ingredients of the present invention may range from 10 to 50 mg/kg body weight per day and can be administrated in a single dose or in divided dose.
  • the amount of the active ingredient actually administrated ought to be determined in light of various relevant factors including the conditions to be treated, the chosen route of administration, the age, sex and body weight of the individual patient, and the severity of the patient's symptom. Therefore, the above dose should not be construed as a limitation to the scope of the invention in any way.
  • the term "health foods” as used herein refers to foods that are prepared by adding the active ingredient to food stuffs including beverages, teas, flavorings, chewing gums, snacks and the like, and exert specific favorable effects on health when taken in. Since the health foods utilize foods as a raw material different from general medicines, they are free from side effects that may be occurred by administering a medicine for a long time, and thus, can be taken in as a food for preventing obesity or an adjunctive for treating obesity.
  • the health foods comprising the Galla Rhois extract or fraction thereof according to the present invention as an active ingredient may be used in combination with other foods or food additives.
  • the amount of the active ingredient and other additives mixed can be appropriately determined within a conventional scope according to the objective for using (prophylactic or therapeutic).
  • the Galla Rhois extract or fraction thereof can be contained in the amount of
  • the content of the Galla Rhois extract or fraction thereof can be lowered to the above range. Further, since the Galla Rhois extract or fraction thereof has no problem with safety and side effects, the content thereof can be also increased over the above range.
  • composition of the present invention can be added.
  • Representative examples of the foods may include meat, sausage, bread, chocolate, candies, snacks, biscuits, pizza, instant noodles, other noodles, chewing gums, dairy products including ice creams, soups, beverages, tea, drinks, alcoholic beverages, vitamin complex and the like.
  • the present invention includes all kinds of health foods being acceptable in common sense.
  • the health drinks of the present invention can further comprise various flavorings or natural carbohydrates as an additive like other ordinary drinks.
  • the natural carbohydrate may be exemplified by monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; polysaccharides such as dextrin and cyclodextrin; and sugar alcohols such as xylitol, sorbitol and erythritol.
  • a sweetening agent natural sweetening agents such as thaumatin and stevia extracts, or synthetic sweetening agents such as saccharin and aspartame can be used.
  • the natural carbohydrates can be used in the amount ranging from 0.01 to 0.04 g, preferably 0.02 to 0.03 g based on 100 mL of the composition according to the present invention.
  • the health foods of the present invention can further comprise various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid as a thickener, pH regulators, stabilizing agents, preservatives, glycerin, alcohol, carbonating agents used in carbonated drinks and the like.
  • the health foods of the present invention can further comprise fruit flesh for the manufacture of natural fruit juice, fruit juice beverages and vegetable beverages.
  • the ingredients can be used alone or in combination thereof.
  • the amount of the additives added is of little important, but it is preferable to add the additives in the amount of 0.01 to 0.1 part by weight based on 100 parts by weight of the composition according to the present invention.
  • Preparation Example 3 Isolation of active ingredients The ethlyacetate fraction 5 g obtained in Preparation Example 2 was subjected to silica gel chromatography (gradient elution from 95:5 to 80:20 of ethylacetate : methanol) using a glass column (5x50 cm) packed with silica beads, to separate 7 fractions.
  • MPLC medium- pressure liquid chromatography
  • Combiflash RF TELEDYNE ISCO
  • RediSep 130 gram vol.
  • n is an integer of from 1 to 2).
  • Preparation Example 4 Preparation of a Galla Rhois extract
  • 1 kg of Galla Rhois was grinded, mixed with 3 L of a 50% acetone solution, extracted at 60 " C for 3 hours with gentle stirring.
  • Example 1 Autophagocytotic activity of a Galla Rhois fraction on preadipocytes and adipocytes 3T3-L1 preadipocytes were maintained in DMEM supplemented with 10% serum and antibiotics, and cultured in a 5% CO2 incubator at 37 °C .
  • Mouse preadipocyte cell line 3T3-L1 was purchased from ATCC (American Type Culture Collection), DMEM, trypsin, FBS (fetal bovine serum) and BCS (bovine calf serum) were purchased from GibcoTM Invitrogen Corporation, and AdipoRedTM Assay Reagent was purchased from Cambrex.
  • 3T3-L1 cells were inoculated into a 96- well plate at a concentration of 1 x 10 4 cells/ ml and cultured until confluence reaches 100%.
  • the cells were treated with an MDI (0.5 mM 3-isobutyl-l-methyxanthine, 1 ⁇ M dexamethason, 10 ⁇ g/mL insulin, Sigma) cocktail. Two days later, the culture medium was replaced with a fresh, and the cells were treated with insulin at the same concentration. Two days later, the culture medium was replaced with a fresh DMEM supplemented with 10% serum, and the cells were further cultured for 4 days.
  • MDI 0.5 mM 3-isobutyl-l-methyxanthine, 1 ⁇ M dexamethason, 10 ⁇ g/mL insulin, Sigma
  • the cells were treated with an ethylacetate fraction of Galla Rhois at a concentration of 7.5 to 125 ⁇ g/mL. Further, the ethylacetate fraction of Galla Rhois was added to the cells with the same concentration simultaneously with the treatment of DMEM so as to examine autophagocytosis activity after the differentiation.
  • the cells treated for 4 days after the induction of differentiation were fixed with 4% paraformaldehyde for 15 minutes, washed with a phosphate buffered saline (PBS) twice, and treated with 0.05 mM monodansyl cadaverine (MDC) for 60 minutes at 37 ° C .
  • the cells were washed with PBS twice and treated with 1 uM ethidium bromide as an internal standard for 10 minutes.
  • DMSO dimethyl sulfoxide
  • Fluorometer analysis monodansyl cadaverine; excitation 356 ran/ emission 545 nm, ethidium bromide; excitation 530 nm/ emission 590 nm
  • Autophagocytosis activity of the Galla Rhois ethylacetate fraction was determined in these cells depending on the change in concentration [Figs. 3 to 5]. The results are shown in the following Table 1.
  • the Galla Rhois fraction exhibited significantly high autophagocytotic activity in a concentration dependent manner during the induction of differentiation and after the differentiation.
  • Example 2 Inhibitory effects on the differentiation of preadipocytes and accumulation of fats in adipocytes
  • 3T3-L1 preadipocytes were maintained in DMEM supplemented with 10% serum and antibiotics, and cultured in a 5% CO 2 incubator at 37 ° C .
  • Murine preadipocyte cell line 3T3-L1 was purchased from ATCC (American Type Culture Collection), DMEM, trypsin, FBS (fetal bovine serum) and BCS (bovine calf serum) were purchased from GibcoTM Invitrogen Corporation, and AdipoRedTM Assay Reagent was purchased from Cambrex.
  • 3T3-L1 cells were inoculated into a 96- well plate at a concentration of 1 ⁇ 10 4 cells/ ml and cultured until reaching 100% confluence.
  • the cells were treated with an MDI (0.5 mM 3-isobuty 1-1 -methy xanthine, 1 ⁇ M dexamethason, 10 ⁇ g/mL insulin, Sigma) cocktail. Two days later, the culture medium was replaced with a fresh one, and the cells were treated with insulin at the same concentration. Two days later, the culture medium was replaced with a fresh DMEM supplemented with 10% serum, and the cells were further cultured for 4 days.
  • MDI 0.5 mM 3-isobuty 1-1 -methy xanthine, 1 ⁇ M dexamethason, 10 ⁇ g/mL insulin, Sigma
  • the cells were treated with a methanol extract and an ethylacetate fraction of Galla Rhois, respectively, at a concentration of 6.25 to 100 ⁇ g/mL. Further, each of the methanol extract and ethylacetate fraction of Galla Rhois was added to the cells with the same concentration simultaneously with the treatment of DMEM so as to examine inhibitory effect on fat accumulation in adipocytes.
  • the adipocytes were fixed with 4% formaldehyde for 5 hours, washed with a phosphate buffered saline (PBS) twice, and treated with a reagent for quantification of intracellular lipid (AdipoRed). After 10 minutes, the resulting cells were subjected to fluorometer analysis (excitation 485 nm; emission 535 nm) and observed under a fluorescence microscope at 488 nm. An EC50 value for each fraction was calculated. In order to examine whether the Galla Rhois extract inhibits fat accumulation in adipocytes, triglyceride was detected by using a TRIGLYZME assay kit (Shinyang, Seoul, Korea) according to the manufacturer's instruction.
  • the Galla Rhois extract (Preparation Example 1) and ethylacetate fraction (Preparation Example 2) showed the highest inhibitory effects on the adipocyte differentiation and fat accumulation in differentiated adipocytes.
  • Example 3 Therapeutic effect of a Galla Rhois extract on obesity in an animal model After 6-week old C57/BL mice (Central Lab. Animal Inc., 18-20 g body weight) were divided into 10 groups, one group of mice were fed a normal diet, and mice in nine other groups were fed a high-fat diet containing 45% fat. After the induction of obesity for 6 weeks, the first and second groups were administered with distilled water (D. W), the third group was administered with 2 mg/kg of Xenical (Roche), and the forth group was administered with 2.4 mg/kg of Reductil (Abbott). The fifth to seventh groups were orally administered everyday with the Galla Rhois extract at a different concentration (10 mg/kg, 20 mg/kg, 40 mg/kg) for 6 weeks, respectively.
  • D. W distilled water
  • the third group was administered with 2 mg/kg of Xenical (Roche)
  • the forth group was administered with 2.4 mg/kg of Reductil (Abbott).
  • the fifth to seventh groups were orally administered everyday with
  • the eighth to tenth groups were orally administered gallotannin everyday at a different concentration (5 mg/kg, 10 mg/kg, 20 mg/kg) for 6 weeks, respectively.
  • the body weight and amount of dietary intake were measured once a week.
  • blood samples were taken from each mouse group, and the levels of triglycerides, neutral lipids and cholesterols in the blood were measured. Further, after the mouse was sacrificed, the liver and epididymis were extracted therefrom, and the level of triglycerides was measured. The results are shown in the following Tables 3 and 4.
  • the Galla Rhois extract exhibited inhibitory effects on the increase in triglycerides, cholesterols and LDL-cholesterols in the obesity- induced mouse in a concentration dependent manner, which confirms that the Galla Rhois extract has prophylactic and therapeutic activities on obesity.
  • the Galla Rhois extract exhibited inhibitory effects on the increase in abdominal and epididymal fats in the obesity- induced mouse in a concentration dependent manner, which confirms that the Galla Rhois extract has prophylactic and therapeutic activities on obesity.
  • the Galla Rhois extract of the present invention exhibits 3- to 4-fold higher inhibitory effect on obesity than the banaba extract.
  • Toxicity test for the Galla Rhois methanol extract and ethylacetate fraction thereof according to the present invention as an active ingredient was carried out as follows.
  • Each of the Galla Rhois methanol extract and ethylacetate fraction was dissolved in 0.5% sodium carboxymethly cellulose, diluted with water, orally administered to mice (10 mice per group) at a concentration of 0, 4, 20, 100, 500 mg/kg, respectively, and then, observed for 7 days. There was no mouse died with single administration and 7 days-repeated administration of the Galla Rhois methanol extract and ethylacetate fraction.
  • a tablet comprising 15 mg of a Galla Rhois extract, an ethlyacetate fraction or a mixture thereof as an active ingredient was prepared according to the following method.
  • the active ingredient 250 g was mixed with lactose 175.9 g, potato starch 180 g and colloidal silicic acid 32 g. After a 10% gelatin solution was added thereto, the resulting mixture was passed through a 14 mesh sieve. Thus sieved mixture was dried, mixed with potato starch 160 g, talc 50 g and magnesium stearate 5 g, and then, formulated into a tablet.
  • Preparation Example 2 Preparation of capsules
  • the active ingredient (Galla Rhois extract, ethlyacetate fraction or a mixture thereof) 500 mg was filled into a soft gelatin capsule, to thereby obtain a capsule.
  • Preparation Example 3 Preparation of beverages
  • the active ingredient (Galla Rhois extract, ethlyacetate fraction or a mixture thereof) 500 mg was dissolved in a proper amount of water, and mixed with vitamin C as a subsidiary ingredient; citric acid, sodium citrate and oligosaccharide as a sweetness additive; and a proper amount of sodium benzoate as a preservative. Then, a total amount of the mixture was adjusted to 100 mL by adding water, to thereby obtain a composition for beverages. At this time, taurine, myoinositol, folic acid, pantoteic acid and the like can be added thereto alone or in combination thereof.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne une composition à extrait de Galla Rhois pour la prévention et le traitement de l'obésité via le mécanisme d'autophagocytose, et elle concerne en particulier la découverte de la faculté qu'a cet extrait ou une fraction de cet extrait d'inhiber la prolifération d'adipocytes en induisant leur autophagocytose, constituant ainsi un procédé qui vise à isoler des principes actifs susceptibles d'être utilisés comme composition pour la prévention et le traitement de l'obésité à partir de Galla Rhois, et donnant une composition pour la prévention et le traitement de l'obésité qui renferme un extrait de Galla Rhois ou une fraction de cet extrait. En l'occurrence, l'extrait considéré selon l'invention a des propriétés dont les effets bénéfiques induisent l'autophagocytose des adipocytes in vitro, l'inhibition de la prise de poids chez un modèle animal établi à partir de l'obésité, la baisse de poids chez un modèle animal établi à partir de la prise de poids, et la diminution des taux de triglycérides et lipoprotéines de faible densité dans le sang. En conséquence, l'extrait selon l'invention peut être utilisé efficacement comme composition pharmaceutique et aliment naturel pour la prévention et le traitement de l'obésité et de ses complications.
PCT/KR2008/006294 2007-11-13 2008-10-24 Composition à extrait de galla rhois pour la prévention et le traitement de l'obésité via le mécanisme d'autophagie WO2009064082A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2007-0115749 2007-11-13
KR20070115749 2007-11-13
KR10-2008-0104394 2008-10-23
KR1020080104394A KR101078002B1 (ko) 2007-11-13 2008-10-23 오배자 추출물을 함유하는 자가포식을 기전으로 한 비만 예방 및 치료용 조성물

Publications (1)

Publication Number Publication Date
WO2009064082A1 true WO2009064082A1 (fr) 2009-05-22

Family

ID=40638896

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2008/006294 WO2009064082A1 (fr) 2007-11-13 2008-10-24 Composition à extrait de galla rhois pour la prévention et le traitement de l'obésité via le mécanisme d'autophagie

Country Status (1)

Country Link
WO (1) WO2009064082A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112444590A (zh) * 2019-09-02 2021-03-05 江阴天江药业有限公司 一种五倍子药材的uplc指纹图谱的构建方法、通过该方法构建的指纹图谱及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009094A1 (fr) * 2002-07-24 2004-01-29 Ohio University Methodes et compositions permettant de traiter les diabetes sucres
US20070254948A1 (en) * 2004-08-23 2007-11-01 Yuko Fukui Lipase Inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009094A1 (fr) * 2002-07-24 2004-01-29 Ohio University Methodes et compositions permettant de traiter les diabetes sucres
US20070254948A1 (en) * 2004-08-23 2007-11-01 Yuko Fukui Lipase Inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHOI, M.-Y. ET AL.: "Effect of Rhus Chinensis Gall extract on liver function, plasma lipid composition and antioxidant system in rats with high fat diet.", J. KOREAN SOC. FOOD SCI. NUTR., vol. 28, no. 3, 1999, pages 632 - 637 *
FROHLICH, B. ET AL.: "Gallotannin biosynthesis: two new galloyltransferases from Rhus typhina leaves preferentally acylating hexa- and heptagalloylglucoses.", PLANTA., vol. 216, 2002, pages 168 - 172 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112444590A (zh) * 2019-09-02 2021-03-05 江阴天江药业有限公司 一种五倍子药材的uplc指纹图谱的构建方法、通过该方法构建的指纹图谱及其应用
CN112444590B (zh) * 2019-09-02 2022-12-02 江阴天江药业有限公司 一种五倍子药材的uplc指纹图谱的构建方法、通过该方法构建的指纹图谱及其应用

Similar Documents

Publication Publication Date Title
RU2576032C2 (ru) Соединения, композиции и способы защиты здоровья головного мозга при нейродегенеративных расстройствах
US20080044453A1 (en) Therapeutic Agent for Treatment of Autoimmune Diseases
US8029831B2 (en) Formulations containing thymoquinone for urinary health
US20150231162A1 (en) Fructose absorption inhibitor
US20230125075A1 (en) Composition Containing Paper Mulberry Extracts
KR20090084439A (ko) 고삼 추출물 또는 이로부터 분리한 프레닐레이티드플라보노이드 화합물을 함유한 당뇨성 합병증의 예방 또는치료용 조성물
EP1618875B1 (fr) Composition destinee a l'inhibition ou a la prevention de la baisse de la densite osseuse
JP2009298769A (ja) 脂肪蓄積抑制用組成物
KR101785495B1 (ko) 감국 추출물 또는 분획물을 유효성분으로 포함하는 비만, 비만 관련 질환 또는 합병증의 예방, 개선 또는 치료용 조성물
KR20160123130A (ko) 감국 추출물 또는 분획물을 유효성분으로 포함하는 비만, 비만 관련 질환 또는 합병증의 예방, 개선 또는 치료용 조성물
KR102080410B1 (ko) 엘더베리 추출물을 유효성분으로 함유하는 남성 갱년기 증후군의 예방, 치료 또는 개선용 조성물
WO2008150074A2 (fr) Composition comprenant les extraits, les fractions et les composés isolés de rhus verniciflua pour la prévention et le traitement des complications diabétiques
KR101078002B1 (ko) 오배자 추출물을 함유하는 자가포식을 기전으로 한 비만 예방 및 치료용 조성물
JPWO2005082390A1 (ja) 脂肪蓄積抑制剤
KR101303306B1 (ko) 으름덩굴 추출물을 함유하는 비만증 치료 및 예방용 조성물
KR101050003B1 (ko) 얼레지 추출물을 유효성분으로 함유하는 비만억제용 조성물
KR101014003B1 (ko) 파이토세라마이드를 포함하는 뇌혈관 질환의 예방 또는 치료용 의약 조성물 및 식품 조성물
WO2009064082A1 (fr) Composition à extrait de galla rhois pour la prévention et le traitement de l'obésité via le mécanisme d'autophagie
KR100839185B1 (ko) 플랜타마조사이드를 유효성분으로 함유하는 당뇨 및당뇨합병증 예방/치료용 조성물
KR101332074B1 (ko) 에스큘레틴을 유효성분으로 함유하는 골 손실 억제용 조성물
KR101910099B1 (ko) 미성숙 감으로부터 가압 열수 방법으로 추출한 추출물 유효성분으로 포함하는 지질대사 개선 또는 항비만용 조성물
KR101436213B1 (ko) 긴잎모시풀 추출물을 포함하는 비만의 예방 또는 치료용 조성물
KR101503583B1 (ko) 머루근 추출물을 포함하는 항비만용 조성물
KR102448274B1 (ko) 보골지 추출물의 조다당 분획물을 유효성분으로 함유하는 골질환의 예방, 개선 또는 치료용 조성물
KR100992995B1 (ko) 피페로날의 신규한 용도

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08850211

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08850211

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)